Cochrane Review Finds PSA Screening Cuts 2 Deaths per 1,000 Men as Overtreatment Risks Persist
Updated
Updated · The Guardian · May 15
Cochrane Review Finds PSA Screening Cuts 2 Deaths per 1,000 Men as Overtreatment Risks Persist
9 articles · Updated · The Guardian · May 15
Six trials covering nearly 800,000 men found PSA screening prevents about 2 prostate cancer deaths per 1,000 men screened—roughly 500 men must be tested to avert 1 death.
The mortality benefit emerged only over long follow-up, especially in the ERSPC trial after 23 years, reinforcing that screening helps mainly when men are likely to live another 10 to 15 years.
Around 30 extra men per 1,000 screened could be diagnosed, many with tumors that would never cause harm, exposing them to surgery, radiotherapy or hormone treatment and complications including incontinence and impotence.
Quality-of-life harms were not systematically measured in the review, but the ProtecT trial found 8% to 47% of treated men reported urinary or sexual problems after radiotherapy or surgery.
The findings stop short of backing universal screening and instead support shared decision-making as the UK reviews advice that currently rejects broad PSA screening while favoring targeted testing for some BRCA1/2 carriers.
PSA screening is back, but is it truly safer? How much do new AI and MRI tools reduce the risk of unnecessary treatments?
Black men face double the prostate cancer risk. Can new screening guidelines finally bridge the deadly healthcare gap?
With a key US health panel stalled, how will new life-saving cancer screening evidence actually reach American patients?
Prostate Cancer Screening in 2026: Modest Mortality Reduction (2 per 1,000) Versus Risks—How New Evidence and Technology Are Shaping Policy and Practice
Overview
The 2026 Cochrane Review marks a turning point in prostate cancer screening, showing that PSA testing modestly reduces deaths—a shift from earlier research that found little life-saving benefit. PSA screening was widely used from the 1990s but later discouraged by medical organizations due to concerns about overdiagnosis and overtreatment. Now, with updated evidence, experts recognize a small but real mortality benefit, prompting renewed debate about balancing these benefits against the risks. This evolution highlights the importance of personalized screening decisions and the ongoing need to refine guidelines as new evidence emerges.